Tagged News

Acadia Pharmaceuticals Appoints Bristol Myers Squibb Veteran to Lead Rare Disease Commercial Strategy

2 months ago

Acadia Pharmaceuticals has appointed Allyson McMillan-Youngblood as Senior Vice President, Rare Disease Franchise, bringing over 20 years of pharmaceutical industry experience.
McMillan-Youngblood previously served as Senior Vice President and Business Unit Head, U.S. Oncology at Bristol Myers Squibb, where she oversaw successful rare tumor acquisitions and product launches.
Her appointment focuses on maximizing DAYBUE's commercial potential and preparing for future rare disease product launches as Acadia expands its portfolio.
The executive brings proven expertise across multiple therapeutic areas including oncology, immunology, CNS, and rare diseases, with a track record of delivering strong commercial results.

2 months ago

Sernova Biotherapeutics announced the resignation of Chairman Ross Haghighat, effective May 24, 2025, with the board accepting his departure and thanking him for his leadership.
The clinical-stage regenerative medicine company is developing its Cell Pouch Bio-hybrid Organ technology as a potential functional cure for type 1 diabetes.
Sernova's innovative approach combines its Cell Pouch with human donor cells or stem cell-derived islet clusters in collaboration with Evotec to restore pancreatic function.
The company's Bio-hybrid Organ platform integrates non-biomaterials with living tissues and initially targets type 1 diabetes and thyroid disorders.

2 months ago

Novo Nordisk CEO Lars Fruergaard Jørgensen announced his resignation after eight years leading the company through significant growth in the obesity treatment market.
The departure follows mounting competitive pressures and a notable decline in share price since mid-2024, prompting the Novo Nordisk Foundation board to seek leadership succession.
Former CEO Lars Rebien Sørensen will join the board as an observer while the company conducts a search for Jørgensen's permanent replacement.
Jørgensen will remain in his role temporarily to ensure a smooth transition during this critical period for the Danish pharmaceutical giant.

2 months ago

Dr. Nicholas Botwood joins Syndax Pharmaceuticals from Bristol Myers Squibb, bringing 25 years of oncology drug development and commercialization experience to accelerate the company's cancer therapy pipeline.
The appointment comes as Syndax continues to expand its portfolio, which includes FDA-approved Revuforj (menin inhibitor) and Niktimvo (axatilimab-csfr), a monoclonal antibody targeting the CSF-1 receptor.
Dr. Botwood succeeds Dr. Neil Gallagher, who oversaw multiple positive data readouts, two product approvals, and the recent submission of Revuforj's supplemental New Drug Application for relapsed or refractory mNPM1 acute myeloid leukemia.

2 months ago

Orca Bio has appointed co-founder and Chief Scientific Officer Nate Fernhoff, Ph.D., as Chief Executive Officer, succeeding Ivan Dimov, Ph.D.
Co-founder Jeroen Bekaert, Ph.D., has been promoted from Chief Operating Officer to President to oversee operations across all organizational areas.
The leadership changes come as the company prepares for a planned 2025 BLA submission to the FDA for Orca-T following positive Phase 3 results.
Orca Bio is accelerating investments in manufacturing infrastructure and commercial operations to support the potential launch of its allogeneic T-cell immunotherapy.

3 months ago

Werner Cautreels, PhD, is retiring as CEO of Traws Pharma effective March 31, 2025, while continuing as a Board Member and special advisor for the next year.
Executive Board Chairman Iain D. Dukes, D Phil, will step in as Interim CEO while maintaining his role as Chairman of the clinical-stage biopharmaceutical company.
Under Cautreels' leadership, Traws Pharma completed a merger with Trawsfynydd and advanced two clinical-stage antiviral candidates targeting bird flu and COVID.